Global Duchenne Muscular Dystrophy Therapeutics Market Research Report 2024(Status and Outlook)

Global Duchenne Muscular Dystrophy Therapeutics Market Research Report 2024(Status and Outlook)



Report Overview:

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

The Global Duchenne Muscular Dystrophy Therapeutics Market Size was estimated at USD 1655.20 million in 2023 and is projected to reach USD 5220.54 million by 2029, exhibiting a CAGR of 21.10% during the forecast period.

This report provides a deep insight into the global Duchenne Muscular Dystrophy Therapeutics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Duchenne Muscular Dystrophy Therapeutics Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Duchenne Muscular Dystrophy Therapeutics market in any manner.

Global Duchenne Muscular Dystrophy Therapeutics Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Bristol-Myers Squibb

FibroGen (US)

Italfarmaco (Italy)

Marathon

NS Pharma (US)

PTC Therapeutics (US)

Pfizer

ReveraGen BioPharma (US)

Santhera Pharmaceuticals (Switzerland)

Sarepta Therapeutics (US)

Market Segmentation (by Type)

Pain Management Drugs

Corticosteroids

Prednisolone

Prednisone

Deflazacort

Market Segmentation (by Application)

Hospitals

Clinics

Home Care

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Duchenne Muscular Dystrophy Therapeutics Market

Overview of the regional outlook of the Duchenne Muscular Dystrophy Therapeutics Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value (USD Billion) data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Note: this report may need to undergo a final check or review and this could take about 48 hours.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Duchenne Muscular Dystrophy Therapeutics Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.


1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Duchenne Muscular Dystrophy Therapeutics
1.2 Key Market Segments
1.2.1 Duchenne Muscular Dystrophy Therapeutics Segment by Type
1.2.2 Duchenne Muscular Dystrophy Therapeutics Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Duchenne Muscular Dystrophy Therapeutics Market Overview
2.1 Global Market Overview
2.1.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Duchenne Muscular Dystrophy Therapeutics Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Duchenne Muscular Dystrophy Therapeutics Market Competitive Landscape
3.1 Global Duchenne Muscular Dystrophy Therapeutics Sales by Manufacturers (2019-2024)
3.2 Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Manufacturers (2019-2024)
3.3 Duchenne Muscular Dystrophy Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Duchenne Muscular Dystrophy Therapeutics Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Duchenne Muscular Dystrophy Therapeutics Sales Sites, Area Served, Product Type
3.6 Duchenne Muscular Dystrophy Therapeutics Market Competitive Situation and Trends
3.6.1 Duchenne Muscular Dystrophy Therapeutics Market Concentration Rate
3.6.2 Global 5 and 10 Largest Duchenne Muscular Dystrophy Therapeutics Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Duchenne Muscular Dystrophy Therapeutics Industry Chain Analysis
4.1 Duchenne Muscular Dystrophy Therapeutics Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Duchenne Muscular Dystrophy Therapeutics Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Duchenne Muscular Dystrophy Therapeutics Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Type (2019-2024)
6.3 Global Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type (2019-2024)
6.4 Global Duchenne Muscular Dystrophy Therapeutics Price by Type (2019-2024)
7 Duchenne Muscular Dystrophy Therapeutics Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Duchenne Muscular Dystrophy Therapeutics Market Sales by Application (2019-2024)
7.3 Global Duchenne Muscular Dystrophy Therapeutics Market Size (M USD) by Application (2019-2024)
7.4 Global Duchenne Muscular Dystrophy Therapeutics Sales Growth Rate by Application (2019-2024)
8 Duchenne Muscular Dystrophy Therapeutics Market Segmentation by Region
8.1 Global Duchenne Muscular Dystrophy Therapeutics Sales by Region
8.1.1 Global Duchenne Muscular Dystrophy Therapeutics Sales by Region
8.1.2 Global Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Region
8.2 North America
8.2.1 North America Duchenne Muscular Dystrophy Therapeutics Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Duchenne Muscular Dystrophy Therapeutics Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Duchenne Muscular Dystrophy Therapeutics Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Duchenne Muscular Dystrophy Therapeutics Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Bristol-Myers Squibb
9.1.1 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Basic Information
9.1.2 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Product Overview
9.1.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Product Market Performance
9.1.4 Bristol-Myers Squibb Business Overview
9.1.5 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics SWOT Analysis
9.1.6 Bristol-Myers Squibb Recent Developments
9.2 FibroGen (US)
9.2.1 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Basic Information
9.2.2 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Product Overview
9.2.3 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Product Market Performance
9.2.4 FibroGen (US) Business Overview
9.2.5 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics SWOT Analysis
9.2.6 FibroGen (US) Recent Developments
9.3 Italfarmaco (Italy)
9.3.1 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Basic Information
9.3.2 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Product Overview
9.3.3 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Product Market Performance
9.3.4 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics SWOT Analysis
9.3.5 Italfarmaco (Italy) Business Overview
9.3.6 Italfarmaco (Italy) Recent Developments
9.4 Marathon
9.4.1 Marathon Duchenne Muscular Dystrophy Therapeutics Basic Information
9.4.2 Marathon Duchenne Muscular Dystrophy Therapeutics Product Overview
9.4.3 Marathon Duchenne Muscular Dystrophy Therapeutics Product Market Performance
9.4.4 Marathon Business Overview
9.4.5 Marathon Recent Developments
9.5 NS Pharma (US)
9.5.1 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Basic Information
9.5.2 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Product Overview
9.5.3 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Product Market Performance
9.5.4 NS Pharma (US) Business Overview
9.5.5 NS Pharma (US) Recent Developments
9.6 PTC Therapeutics (US)
9.6.1 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Basic Information
9.6.2 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Overview
9.6.3 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Market Performance
9.6.4 PTC Therapeutics (US) Business Overview
9.6.5 PTC Therapeutics (US) Recent Developments
9.7 Pfizer
9.7.1 Pfizer Duchenne Muscular Dystrophy Therapeutics Basic Information
9.7.2 Pfizer Duchenne Muscular Dystrophy Therapeutics Product Overview
9.7.3 Pfizer Duchenne Muscular Dystrophy Therapeutics Product Market Performance
9.7.4 Pfizer Business Overview
9.7.5 Pfizer Recent Developments
9.8 ReveraGen BioPharma (US)
9.8.1 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Basic Information
9.8.2 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Product Overview
9.8.3 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Product Market Performance
9.8.4 ReveraGen BioPharma (US) Business Overview
9.8.5 ReveraGen BioPharma (US) Recent Developments
9.9 Santhera Pharmaceuticals (Switzerland)
9.9.1 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Basic Information
9.9.2 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Product Overview
9.9.3 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Product Market Performance
9.9.4 Santhera Pharmaceuticals (Switzerland) Business Overview
9.9.5 Santhera Pharmaceuticals (Switzerland) Recent Developments
9.10 Sarepta Therapeutics (US)
9.10.1 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Basic Information
9.10.2 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Overview
9.10.3 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Market Performance
9.10.4 Sarepta Therapeutics (US) Business Overview
9.10.5 Sarepta Therapeutics (US) Recent Developments
10 Duchenne Muscular Dystrophy Therapeutics Market Forecast by Region
10.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size Forecast
10.2 Global Duchenne Muscular Dystrophy Therapeutics Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Country
10.2.3 Asia Pacific Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Region
10.2.4 South America Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Duchenne Muscular Dystrophy Therapeutics by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Duchenne Muscular Dystrophy Therapeutics Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Duchenne Muscular Dystrophy Therapeutics by Type (2025-2030)
11.1.2 Global Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Duchenne Muscular Dystrophy Therapeutics by Type (2025-2030)
11.2 Global Duchenne Muscular Dystrophy Therapeutics Market Forecast by Application (2025-2030)
11.2.1 Global Duchenne Muscular Dystrophy Therapeutics Sales (K Units) Forecast by Application
11.2.2 Global Duchenne Muscular Dystrophy Therapeutics Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings